PDCD1LG2 and neoplasm: Many studies have attempted to identify predictors of treatment response, including tumor expression of PD-L1, PD-L2, IFNγ, CD73, and CXCL9, as well as tumor mutation burden and the formation of tertiary lymphoid structures (TLSs), but these do not fully explain the variability of patient responses (4, –6).